References
- Waissbluth S, Peleva E, Daniel SJ. Platinum-induced ototoxicity: a review of prevailing ototoxicity criteria. Eur Arch Otorhinolaryngol. 2017;274:1187–1196.
- Markantonis SL, Markou N, Fousteri M, et al. Penetration of colistin into cerebrospinal fluid. Antimicrob Agents Chemother. 2009;53:4907–4910.
- Livermore DM. Bacterial resistance: origins, epidemiology, and impact. Clin Infect Dis. 2003;36:S11–S23.
- Kwa A, Kasiakou SK, Tam VH, et al. Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infect Ther. 2007;5:811–821.
- Bergen PJ, Landersdorfer CB, Zhang J, et al. Pharmacokinetics and pharmacodynamics of ‘old. Diagn Microbiol Infect Dis. 2012;74:213–223.
- Giamarellou H. Multidrug-resistant gram-negative bacteria: how to treat and for how long. Int J Antimicrob Agents. 2010;36:S50–S54.
- Lim LM, Ly N, Anderson D, et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy 2010;30:1279–1291.
- Boisson M, Gregoire N, Couet W, et al. Colistin in critically ill patients. Minerva Anestesiol. 2013;79:200–208.
- Şua S, Dikici N. Kolistin. Yoğun Bakim Derg. 2010;30:1279–1291.
- Park YH. Stem cell therapy for sensorineural hearing loss, still alive? J Audiol Otol. 2015;19:63–67.
- Seligmann H, Podoshin L, Ben-David J, et al. Drug-induced tinnitus and other hearing disorders. Drug Saf. 1996;14:198–212.
- Camacho-Gonzalez A, Spearman PW, Stoll BJ. Neonatal infectious diseases: evaluation of neonatal sepsis. Pediatr Clin North Am. 2013;60:367–389.
- Tsai MH, Chu SM, Hsu JF, et al. Risk factors and outcomes for multidrug-resistant gram-negative bacteremia in the NICU. Pediatrics 2014;133:e322–e329.
- Isturiz R. Global resistance trends and the potential impact on empirical therapy. Int J Antimicrob Agents 2008;32:S201–S206.
- Giske CG, Monnet DL, Cars O, et al. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother. 2008;52:813–821.
- Nation RL, Li J. Colistin in the 21st century. Curr Opin Infect Dis. 2009;22:535–543.
- Berlana D, Llop JM, Fort E, et al. Use of colistin in the treatment of multiple-drug-resistant gram-negative infections. Am J Health Syst Pharm. 2005;62:39–47.
- Akyıldız N. Kulak Hastalıkları Ve Mikrocerrahisi. Bk. 2. Ankara: Bilimsel Tıp Yayınevi; 2002.
- Hall JW, 3rd, Baer JE, Chase PA, et al. Clinical application of otoacoustic emissions: what do we know about factors influencing measurement and analysis? Otolaryngol Head Neck Surg. 1994;110:22–38.
- Plinkert PK, Bootz F, Vossieck T. Influence of static middle ear pressure on transiently evoked otoacoustic emissions and distortion products. Eur Arch Otorhinolaryngol. 1994;25:95–99.
- Roland JT, Cohen NL. Vestibular and auditory oto-toxicity. In: Cummings CW, Fredrickson JM, Harker LA, et al., editors. Otolaryngology Head & Neck Surgery. 3rd ed. Vol. 4. St. Louis: Mosby-Year Book; 1998. p. 3186–3197.
- Priuska EM, Schacht J. Mechanism and prevention of aminoglycoside ototoxicity: outer hair cells as targets and tools. Ear Nose Throat J. 1997;76:164–166, 168, 170.
- Koch-Weser J, Sidel VW, Federman EB, et al. Adverse effects of sodium colistimethate. Ann Intern Med. 1970;72:857–868.
- Campbell KC, Durrant J. Audiologic monitoring for ototoxicity. Otolaryngol Clin North Am. 1993;26:903–914.